Search Results
Dr. Zakashansky on the Benefit of Maintenance Olaparib in BRCA+ Ovarian Cancer
Dr. Zakashansky on Repeat Exposure to PARP Inhibitors in Patients With Ovarian Cancer
Olaparib Maintenance for Recurrent Ovarian Cancer
Maintenance Olaparib in Patients With Ovarian Cancer
7-year OS from SOLO1: sustained benefit with maintenance olaparib
Dr. Willmott on FDA Approval of Maintenance Olaparib in Ovarian Cancer
Dr. Liu on Cediranib/Olaparib in Recurrent Ovarian Cancer
The Impact of PAOLA-1 on Frontline Treatment of Ovarian Cancer
Olaparib approved in Scotland as a first-line treatment for advanced ovarian cancers
Expert report on survival data from pivotal trials with PARP inhibitors for BRCA-mut. Ovarian Cancer
Learn all about PARP inhibitors with Dr Jon Krell, Consultant Medical Oncologist
Case 2: Olaparib in BRCA-Mutated Ovarian Cancer